Table 3.
Other key base case model inputs.
| Parameter | Base case value |
|---|---|
| Model settings | |
| Time horizon1 | Lifetime (57 years maximum) |
| Discount rate | |
| For costs (initial 30 years) | 2.50% (22) |
| For costs (over 30 years) | 1.50% (22) |
| For outcomes (initial 30 years) | 2.50% (22) |
| For outcomes (over 30 years) | 1.50% (22) |
| Long-term AEs of CT | |
| Probability of AML | 0.62% (27) |
| HR for CHF with CT | 1.61 (29) |
| Mortality | |
| Median OS in the DR state (months) | 63.90 (30) |
| 5-year AML death probability | 76.00% (31) |
| Utilities | |
| Utility adjustment factor for France | 1.043 (35) |
| Utility in | |
| Recurrence-free state | 0.860 (62) |
| DR state | 0.715 (62) |
| AML state | 0.271 (63) |
| CHF state | 0.551 (29) |
| Utility decrement for CT | 0.040 (36) |
| Costs | |
| Test cost (Oncotype DX® test) | €1,850 (46) |
| Recurrence-free cost – Year 1 | |
| N0 and age <50 years | €3,777 (unpublished data) |
| N0 and age ≥50 years | €2,973 (unpublished data) |
| N1 and age ≥50 years | €3,444 (unpublished data) |
| Recurrence-free cost—Years 2–5 | €604 (48) |
| Recurrence-free cost—Years 6+ | €604 (48) |
| CDK 4/6 costs in the DR state | €14,395 (47) |
| Disease management cost in the DR state | €6,516 (48) |
| AML one-off cost | €23,970 (49) |
| AML subsequent cost | €5,806 (48) |
| CHF one-off cost | €1,888 (49) |
| CHF subsequent cost | €1,148 (48) |
| Terminal care | €4,606 (49) |
| Transportation costs—CT | |
| N0 and age < 50 years | €2,906 (unpublished data) |
| N0 and age ≥ 50 years | €1,738 (unpublished data) |
| N1 and age ≥ 50 years | €1,200 (unpublished data) |
| Transportation costs – ET | |
| N0 and age < 50 years | €255 (unpublished data) |
| N0 and age ≥ 50 years | €925 (unpublished data) |
| N1 and age ≥ 50 years | €337 (unpublished data) |
| Sick leave related to CT | |
| N0 and age < 50 years | €6,316 (unpublished data) |
| N0 and age ≥ 50 years | €5,235 (unpublished data) |
| N1 and age ≥ 50 years | €10,609 (unpublished data) |
| Additional costs due to CT2 | |
| N0 and age < 50 years | €2,063 (unpublished data) |
| N0 and age ≥ 50 years | €4,479 (unpublished data) |
| N1 and age ≥ 50 years | €3,619 (unpublished data) |
| Costs of ET—N0 and age < 50 years | €91 (47) |
| Costs of ET—N0/N1 and age ≥ 50 years | €223 (47) |
AML, acute myeloid leukemia; CDK, cyclin-dependent kinase; CHF, chronic heart failure; CT, chemotherapy; DR, distant recurrence; ET, endocrine therapy; HR, hazard ratio; N0, node-negative disease; N1, 1–3 invaded lymph nodes; OS, overall survival; RS, recurrence score; AEs, adverse events.
1Lifetime horizon was defined as sufficient for the patient cohort to reach 100 years of age. Therefore, the number of years in the model differed depending on the age at model entry and was 57 years for premenopausal women with N0 disease, 39 years for postmenopausal women with N1 disease, and 36 years for post-menopausal women with N0 disease.
2Additional costs due to CT were estimated from OPTISOINS01 data as the difference between the average cost per patient treated with CT and the average cost per patient not treated with CT. We assumed that they included all CT-related costs and associated adverse event costs.